SELLAS Life Sciences posts $10.1M Q3 loss as pivotal leukemia trial results approach

Share

SELLAS Life Sciences recorded a $10.1 million loss in the third quarter as investors awaited results from the Phase 3 REGAL trial of galinpepimut S, an immunotherapy for acute myeloid leukemia. On October 28, the company said the study had reached its prespecified 80th event, triggering the final analysis of its primary overall survival endpoint. Following database lock, unblinding and statistical analysis, preliminary results are expected in the fourth quarter of 2026. SELLAS is also developing SLS009, a CDK9 inhibitor being evaluated in combination with existing treatments for acute myeloid leukemia. The company reported $138.3 million in cash and cash equivalents as of June 30.

Source: Read the original article

Disclaimer: this content is for information purposes only and is not financial advice. Cryptocurrencies are highly volatile: you may lose all of your capital. Always do your own research. Legal notice
Telemac
Telemachttp://cryptoinfo.ch
Passionné de nouvelles technologies, j’explore l’univers de la blockchain et des cryptomonnaies pour partager l’actualité et les innovations du secteur.

Read More

Items